These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

93 related items for PubMed ID: 3502171

  • 1. Chemotherapy subsequent to recombinant interleukin-2 immunotherapy: protocol for enhanced tumoricidal activity.
    Ades EW, McKemie CR, Wright S, Peacocke N, Pantazis C, Lockhart WL.
    Nat Immun Cell Growth Regul; 1987; 6(5):260-8. PubMed ID: 3502171
    [Abstract] [Full Text] [Related]

  • 2. An immunochemotherapy protocol for enhanced tumoricidal activity: in vivo treatment with IL-2 prior to chemotherapy.
    Lockhart WL, McKemie CR, Wright S, Peacocke N, Pantazis C, Ades EW.
    J Clin Lab Immunol; 1987 Oct; 24(2):101-3. PubMed ID: 3501806
    [Abstract] [Full Text] [Related]

  • 3. Immunohistochemical characterisation of immunological changes at the tumour site after chemo-immunotherapy with doxorubicin, interleukin-2 and interferon-gamma.
    Lumsden AJ, Codde JP, Van der Meide PH, Gray BN.
    Anticancer Res; 1996 Oct; 16(3A):1145-54. PubMed ID: 8702226
    [Abstract] [Full Text] [Related]

  • 4. [Experimental study on the optimal treatment schedule for combination of BRM (immunostimulators, cultured killer cells or interleukin-2) and chemotherapy].
    Kan N, Okino T, Satoh K, Mise K, Teramura Y, Yamasaki S, Harada T, Ohgaki K, Tobe T.
    Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1421-7. PubMed ID: 2389941
    [Abstract] [Full Text] [Related]

  • 5. Efficacy and mechanisms of action of rmB7.2-Ig as an antitumor agent in combination with Adriamycin and Cytoxan chemotherapy.
    Zhou H, Sequeira M, Goad ME, Erickson J, Wong A, Clark E, Dunussi-Joannopoulos K, Li RC, Friedrich S, Hayes LL, Wolf SF.
    Clin Immunol; 2001 Dec; 101(3):303-14. PubMed ID: 11726223
    [Abstract] [Full Text] [Related]

  • 6. Therapeutic efficacy of tumor-derived heat shock protein 70 immunotherapy combining interleukin-2 on tumor-bearing mice.
    Fu Q, Meng F, Shen X, Guo R.
    Chin Med J (Engl); 2003 Feb; 116(2):288-91. PubMed ID: 12775249
    [Abstract] [Full Text] [Related]

  • 7. Immunotherapy of murine and human tumors in mice with lymphokines and interleukin-2-propagated lymphocytes.
    Kedar E, Chriqui-Zeira E, Kyriazis AP.
    J Biol Response Mod; 1984 Oct; 3(5):517-26. PubMed ID: 6334139
    [Abstract] [Full Text] [Related]

  • 8. Chemoimmunotherapy in mice carrying HPV16-associated, MHC class I+ and class I- tumours: Effects of CBM-4A potentiated with IL-2, IL-12, GM-CSF and genetically modified tumour vaccines.
    Indrová M, Bubeník J, Mikysková R, Mendoza L, Símová J, Bieblová J, Jandlová T, Jinoch P, Smahel M, Vonka V, Pajtasz-Piasecka E.
    Int J Oncol; 2003 Mar; 22(3):691-5. PubMed ID: 12579325
    [Abstract] [Full Text] [Related]

  • 9. Antitumor efficacy of interleukin-2 alone and in combination with adriamycin and dacarbazine in murine solid tumor systems.
    LoRusso PM, Aukerman SL, Polin L, Redman BG, Valdivieso M, Biernat L, Corbett TH.
    Cancer Res; 1990 Sep 15; 50(18):5876-82. PubMed ID: 2393858
    [Abstract] [Full Text] [Related]

  • 10. Paracrine immunotherapy with interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors.
    Sampath P, Hanes J, DiMeco F, Tyler BM, Brat D, Pardoll DM, Brem H.
    Cancer Res; 1999 May 01; 59(9):2107-14. PubMed ID: 10232596
    [Abstract] [Full Text] [Related]

  • 11. Combination nonviral interleukin-2 gene immunotherapy for head and neck cancer: from bench top to bedside.
    O'Malley BW, Li D, McQuone SJ, Ralston R.
    Laryngoscope; 2005 Mar 01; 115(3):391-404. PubMed ID: 15744147
    [Abstract] [Full Text] [Related]

  • 12. "In vivo effects of rIL-2 pretreatment on chemotherapeutically induced in vivo natural cytolytic hyporesponsiveness".
    Lockhart WL, Peacocke N, Ades EW.
    Immunopharmacol Immunotoxicol; 1987 Mar 01; 9(2-3):177-93. PubMed ID: 3501795
    [Abstract] [Full Text] [Related]

  • 13. Combined immunogene therapy of IL-6 and IL-15 enhances anti-tumor activity through augmented NK cytotoxicity.
    Lin CY, Chuang TF, Liao KW, Huang YJ, Pai CC, Chu RM.
    Cancer Lett; 2008 Dec 18; 272(2):285-95. PubMed ID: 18760876
    [Abstract] [Full Text] [Related]

  • 14. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
    Teicher BA, Ara G, Buxton D, Leonard J, Schaub RG.
    Clin Cancer Res; 1997 Sep 18; 3(9):1661-7. PubMed ID: 9815857
    [Abstract] [Full Text] [Related]

  • 15. Treating tumor-bearing mice with low-dose gamma-interferon plus tumor necrosis factor alpha to diminish immune suppressive granulocyte-macrophage progenitor cells increases responsiveness to interleukin 2 immunotherapy.
    Pak AS, Ip G, Wright MA, Young MR.
    Cancer Res; 1995 Feb 15; 55(4):885-90. PubMed ID: 7850804
    [Abstract] [Full Text] [Related]

  • 16. Improved immunotherapy of a recombinant carcinoembryonic antigen vaccinia vaccine when given in combination with interleukin-2.
    McLaughlin JP, Schlom J, Kantor JA, Greiner JW.
    Cancer Res; 1996 May 15; 56(10):2361-7. PubMed ID: 8625312
    [Abstract] [Full Text] [Related]

  • 17. Anti-tumor effects of local irradiation in combination with peritumoral administration of low doses of recombinant interleukin-2 (rIL-2).
    Jürgenliemk-Schulz IM, Renes IB, Rutgers DH, Everse LA, Bernsen MR, Den Otter W, Battermann JJ.
    Radiat Oncol Investig; 1997 May 15; 5(2):54-61. PubMed ID: 9303058
    [Abstract] [Full Text] [Related]

  • 18. Administration of systemic or local interleukin-2 enhances the anti-tumor effects of interleukin-12 gene therapy.
    Pappo I, Tahara H, Robbins PD, Gately MK, Wolf SF, Barnea A, Lotze MT.
    J Surg Res; 1995 Feb 15; 58(2):218-26. PubMed ID: 7861776
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of antitumor activity of polyethylene glycol-coated liposomal doxorubicin with soluble and liposomal interleukin 2.
    Cabanes A, Even-Chen S, Zimberoff J, Barenholz Y, Kedar E, Gabizon A.
    Clin Cancer Res; 1999 Mar 15; 5(3):687-93. PubMed ID: 10100723
    [Abstract] [Full Text] [Related]

  • 20. Tumour burden and interleukin-2 dose affect the interaction between low-dose total body irradiation and interleukin 2.
    Safwat A, Aggerholm N, Roitt I, Overgaard J, Hokland M.
    Eur J Cancer; 2004 Jun 15; 40(9):1412-7. PubMed ID: 15177501
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.